Systematic Review for the 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines - Wilson, Peter W.F.; Polonsky, Tamar S.; Miedema, Michael D.; Khera, Amit; Kosinski, Andrzej S.; Kuvin, Jeffrey T. (Circulation (New York, N.Y.), 2019)
Keywords: Anticholesteremic Agents - adverse effects; Anticholesteremic Agents - therapeutic use; Biomarkers - blood; Cardiology - standards; Cardiovascular Diseases - blood; Cardiovascular Diseases - diagnosis; Cardiovascular Diseases - epidemiology; Cardiovascular Diseases - prevention & control; Cholesterol - blood; Consensus; Evidence-Based Medicine - standards; Humans; Hyperlipidemias - blood; Hyperlipidemias - diagnosis; Hyperlipidemias - drug therapy; Hyperlipidemias - epidemiology; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Treatment Outcome; cardiovascular disease; patient compliance; risk assessment; lipids; drug therapy; risk reduction discussion; hydroxymethylglutaryl-CoA reductase inhibitors/statins; risk treatment discussion, secondary prevention; proprotein convertase subtilisin/kexin type 9 inhibitor (PCSK9) inhibitors; biomarkers, coronary artery calcium score; diabetes mellitus; hypercholesterolemia; pharmacological; AHA Scientific Statements; Guidelines; cholesterol, LDL-cholesterol; ezetimibe; primary prevention